Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0KCRUX
ADC Name
Anti-CD70 ADC 12-2
Synonyms
Anti-CD70-ADC-12-2
   Click to Show/Hide
Organization
Merck & Co., Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Renal cell carcinoma [ICD11:2C90]
Investigative
Drug-to-Antibody Ratio
2
Structure
Antibody Name
Anti-CD70 mAb 2H5
  Antibody Info 
Antigen Name
CD70 antigen (CD70)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Anti-CD70 ADC 12-2 linker
Conjugate Type
The drug linker was conjugated to the unnatural amino acid (UAA) para-azido phenylalanine (p-AF)
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.7
ug/mL
786-O cells
Renal cell carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.70 ug/mL Positive CD70 expression (CD70 +++/++)
Method Description
786-O cells were plated at 30K cells/well overnight at 37°C in RPMI Media assuggested by ATCC (+ 10% HI FBS). Cells were stimulated with ADCs for 2, 6, or 24 hours at 37°C.
In Vitro Model Renal cell carcinoma 786-O cells CVCL_1051
References
Ref 1 Phosphate based linkers for intracellular delivery of drug conjugates; 2015-10-08.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.